Zimmer Biomet Holdings Inc (ZBH) Given Average Recommendation of “Buy” by Brokerages

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) have been assigned an average recommendation of “Buy” from the twenty-six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $137.00.

Several research analysts have issued reports on the company. Goldman Sachs Group upgraded Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price objective for the company in a research note on Tuesday, December 19th. Canaccord Genuity reiterated a “hold” rating and set a $125.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Wells Fargo & Co upgraded Zimmer Biomet from a “market perform” rating to an “outperform” rating in a research note on Tuesday, December 19th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $142.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, December 12th.

Zimmer Biomet (ZBH) opened at $124.74 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a 12 month low of $103.62 and a 12 month high of $133.49. The stock has a market capitalization of $25,260.00, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 1.93 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the prior year, the company earned $1.79 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. equities analysts anticipate that Zimmer Biomet will post 8.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is presently 29.91%.

A number of institutional investors have recently bought and sold shares of ZBH. Longview Partners Guernsey LTD boosted its holdings in Zimmer Biomet by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after acquiring an additional 1,128,973 shares during the last quarter. Koch Industries Inc. boosted its holdings in Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in Zimmer Biomet by 249.3% in the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after acquiring an additional 727,925 shares during the last quarter. BlackRock Inc. boosted its holdings in Zimmer Biomet by 4.1% in the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after acquiring an additional 679,080 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Zimmer Biomet by 20.2% in the second quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock valued at $514,919,000 after acquiring an additional 673,079 shares during the last quarter. Institutional investors and hedge funds own 85.92% of the company’s stock.

WARNING: This report was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/01/05/zimmer-biomet-holdings-inc-zbh-given-average-recommendation-of-buy-by-brokerages.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply